BioNexus Gene Lab (BGLC) Accumulated Expenses (2018 - 2026)

BioNexus Gene Lab (BGLC) has 9 years of Accumulated Expenses data on file, last reported at $589700.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 105.34% year-over-year to $589700.0; the trailing twelve-month figure through Mar 2026 stood at $589700.0 (up 105.34% YoY), and the FY2025 full-year result was $126036.0, down 55.64% from the prior year.
• Accumulated Expenses improved to $589700.0 in Q1 2026, from $126036.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $589700.0 in Q1 2026 to a low of $29776.0 in Q3 2023.
• A 5-year average of $184598.5 and a median of $169883.0 in 2024 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 881.11% in 2024 and slumped 55.64% in 2025, its largest moves.
• Tracing BGLC's Accumulated Expenses over 5 years: stood at $103370.0 in 2022, then jumped by 75.01% to $180912.0 in 2023, then surged by 57.04% to $284108.0 in 2024, then tumbled by 55.64% to $126036.0 in 2025, then jumped by 367.88% to $589700.0 in 2026.
• Business Quant data shows BGLC's Accumulated Expenses at $589700.0 in Q1 2026, $126036.0 in Q4 2025, and $375380.0 in Q3 2025.